Welcome to Asklepion Pharmaceuticals.

Asklepion is focused on the discovery, development, and commercialization of pharmaceutical products to help patients who have little to no therapeutic options, due to the rarity of their conditions.

Asklepion aims to provide treatment options for children with rare diseases.

About UsClinical Trials

Latest News

Asklepion Pharmaceuticals, LLC announces receipt of Orphan Drug Designation from U.S. FDA. January 9, 2017

FDA has granted orphan drug designation to L-citrulline for prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients. January 9, 2017

L-citrulline pivotal Phase III trial initiated in July 2016

Liquid formulation of ursodeoxycholic acid strategically divested to Retrophin, Inc. in June 2016

Cholbam® (cholic acid) oral capsules approved by the F.D.A. in March 2015

Industry Awards and Recognitions

March, 2016. Asklepion Pharmaceuticals, was awarded a 2016 Rare Impact Award by the National Organization for Rare Disorders (NORD).
January, 2016. Asklepion Pharmaceutical’s first product Cholbam® (cholic acid) is listed in the U.S. Food and Drug Administration’s Novel Drug Summary for 2015.